Bicara Therapeutics (BCAX) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Bicara Therapeutics (NASDAQ: BCAX):

• 11/11/2026 – Bicara Therapeutics had its price target lowered by HC Wainwright from $42.00 to $36.00. They now have a “buy” rating on the stock.
• 11/10/2026 – Bicara Therapeutics had its “market outperform” rating reaffirmed by Citigroup.
• 11/10/2026 – Bicara Therapeutics had its price target lowered by Morgan Stanley from $41.00 to $30.00. They now have an “overweight” rating on the stock.
• 11/10/2026 – Bicara Therapeutics had its price target lowered by Stifel Nicolaus from $45.00 to $43.00. They now have a “buy” rating on the stock.
• 11/10/2026 – Bicara Therapeutics had its price target lowered by BTIG Research from $39.00 to $37.00. They now have a “buy” rating on the stock.
• 10/31/2026 – Bicara Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/30/2026 – Bicara Therapeutics was downgraded by The Goldman Sachs Group from “neutral” to “sell”. They now have a $8.00 price target on the stock, down from $20.00.
• 10/29/2026 – Bicara Therapeutics had its price target lowered by Wedbush from $33.00 to $24.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Bicara Therapeutics had its “buy” rating reaffirmed by Benchmark.
• 10/20/2026 – Bicara Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley.
• 10/20/2026 – Bicara Therapeutics was given a new $41.00 price target by Morgan Stanley.
• 10/19/2026 – Bicara Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
• 10/2/2026 – Bicara Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/22/2026 – Bicara Therapeutics was downgraded by HSBC to “equal weight”.

Bicara Therapeutics Trading Down 3.0%

BCAX traded down $0.30 during trading on Friday, hitting $9.81. The stock had a trading volume of 207,568 shares, compared to its average volume of 764,668. The firm has a market cap of $651.22 million, a PE ratio of -2.83 and a beta of -0.33. Bicara Therapeutics Inc. has a 12 month low of $7.87 and a 12 month high of $30.99. The company has a 50 day simple moving average of $17.10 and a 200-day simple moving average of $20.81.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22). As a group, sell-side analysts anticipate that Bicara Therapeutics Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Bicara Therapeutics

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the transaction, the chief executive officer owned 181,641 shares of the company’s stock, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.80% of the company’s stock.

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.